SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-22-015745
Filing Date
2022-08-09
Accepted
2022-08-09 07:16:18
Documents
70
Period of Report
2022-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q kymr-20220630.htm   iXBRL 10-Q 3365222
2 EX-31.1 kymr-ex31_1.htm EX-31.1 21268
3 EX-31.2 kymr-ex31_2.htm EX-31.2 21078
4 EX-32.1 kymr-ex32_1.htm EX-32.1 12185
5 EX-32.2 kymr-ex32_2.htm EX-32.2 11994
  Complete submission text file 0000950170-22-015745.txt   11284589

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT kymr-20220630_def.xml EX-101.DEF 249487
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT kymr-20220630_lab.xml EX-101.LAB 544969
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT kymr-20220630_cal.xml EX-101.CAL 54949
9 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT kymr-20220630.xsd EX-101.SCH 64305
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT kymr-20220630_pre.xml EX-101.PRE 391550
64 EXTRACTED XBRL INSTANCE DOCUMENT kymr-20220630_htm.xml XML 2270014
Mailing Address 200 ARSENAL YARDS BLVD., SUITE 230 WATERTOWN MA 02472
Business Address 200 ARSENAL YARDS BLVD., SUITE 230 WATERTOWN MA 02472 857-285-5314
Kymera Therapeutics, Inc. (Filer) CIK: 0001815442 (see all company filings)

IRS No.: 812992166 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39460 | Film No.: 221146383
SIC: 2836 Biological Products, (No Diagnostic Substances)